Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
English Version English Version
  MedUni Wien  trenner  Intranet  trenner  MedUni Wien - Shop  trenner  Universitätsbibliothek  trenner  Universitätsklinikum AKH Wien  trenner
 
Krebsforschung.png
 
 
 
Hauptnavigation
  • Home
  • Mission Statement
    • Chronik
    • 50 Jahre Institut für Krebsforschung
    • Imagevideo: Institut für Krebsforschung
  • Forschung
    • Forschungsschwerpunkte
    • Forschungsgruppen
    • Wissenschaftliche Services - Core Facilities
  • Lehre
    • Vorlesungen und Seminare des Institutes
    • Universitätslehrgang Toxikologie für Postgraduierte
    • PhD Program Inflammation and Immunity
    • PhD Program IPPTO Translational Oncology
    • PhD Programm Malignant Diseases
    • PhD Programm Clinical and Experimental Oncology
  • Kontakt
    • Kontakt
    • Lageplan
 
Forschung / Forschungsschwerpunkte / Angewandte und experimentelle Onkologie / Klaus Holzmann
 
Subnavigation
  • Forschungsschwerpunkte
    • Zelluläre und molekulare Tumorbiologie
    • Angewandte und experimentelle Onkologie
      • Walter Berger
      • Martin Filipits
      • Petra Heffeter
      • Michael Grusch
      • Klaus Holzmann
        • Research Projects
        • Group Members
        • Former Group Members
        • Teaching
        • Short CV
      • Hedwig Sutterlüty
    • Sicherheit chemischer Substanzen und Krebsprävention
    • Progression und Metastasierung von Tumoren
  • Forschungsgruppen
  • Wissenschaftliche Services - Core Facilities


Inhaltsbereich

 

Klaus Holzmann, Ao.Univ.-Prof. Dipl.-Ing. Dr.
Gruppenleiter

E-Mail: klaus.holzmann [at] meduniwien [dot] ac [dot] at
Phone: +43 (0)1 40160 - 57530 (Office), 57535 (Lab)
Fax: +43 (0)1 40160 - 957500

Research Focus

The main focus of our research is analyses of two essential hallmarks of tumors, immortality and growth factor signaling. In detail, we study the telomere maintenance mechanisms (TMMs) and the fibroblast growth factor receptor (FGFR) signaling pathway. We aim to characterize the mechanism behind in various tumors and respective tumor cell models of human and canine origin. We aim to translate this knowledge into novel therapeutic strategies or combinations with established ones.

Financial support: Jubiläumsfonds der Österreichischen Nationalbank, Initiative Krebsforschung, Hochschuljubiläumsstiftung der Stadt Wien, Herzfelder Foundation, Fonds des Bürgermeisters der Bundeshauptstadt Wien

Group Members

Selected Publications

Prevalence and potentially prognostic value of C-circles associated with alternative lengthening of telomeres in canine appendicular osteosarcoma
Bicanova L, Kreilmeier-Berger T, Reifinger M, Holzmann K., Kleiter M.
Vet Comp Oncol. 2020 Nov 19. doi: 10.1111/vco.12665. PMID: 33211388

Hot Spot TERT Promoter Mutations Are Rare in Sporadic Pancreatic Neuroendocrine Neoplasms and Associated with Telomere Length and Epigenetic Expression Patterns.
Posch A, Hofer-Zeni S, Klieser E, Primavesi F, Naderlinger E, Brandstetter A, Filipits M, Urbas R, Swiercynski S, Jäger T, Winkelmann P, Kiesslich T, Lu L, Neureiter D, Stättner S, Holzmann K.
Cancers (Basel). 2020 Jun 19;12(6):E1625. doi: 10.3390/cancers12061625

Importance of Translational Research for Targeting Fibroblast Growth Factor Receptor Signaling in Cancer.
Holzmann K, Marian B.
Cells. 2019 Oct 2;8(10):1191. doi: 10.3390/cells8101191.

Epigenetic Regulation of Telomere Maintenance for Therapeutic Interventions in Gliomas.
Naderlinger E, Holzmann K;
Genes (Basel). 2017 May 17;8(5). pii: E145. doi: 10.3390/genes8050145.

Epithelial splicing regulatory protein 1 and 2 paralogues correlate with splice signatures and favorable outcome in human colorectal cancer.
Deloria AJ, Höflmayer D, Kienzl P, Łopatecka1 J, Sampl S, Klimpfinger M, Braunschmid T, Bastian F, Lu L, Marian B, Stättner S, Holzmann K;
Oncotarget. 2016 Nov 8;7(45):73800-73816. doi: 10.18632/oncotarget.12070.

Alternative lengthening of telomeres does exist in various canine sarcomas.
Kreilmeier T, Sampl S, Deloria AJ, Walter I, Reifinger M, Hauck M, Borst LB, Holzmann K, Kleiter M.; Mol Carcinog. 2016 Sep 1. doi: 10.1002/mc.22546.

LINE-1 induces hTERT and ensures telomere maintenance in tumour cell lines.
Aschacher T, Wolf B, Enzmann F, Kienzl P, Messner B, Sampl S, Svoboda M, Mechtcheriakova D, Holzmann K, Bergmann M.
Oncogene. 2016 Jan 7;35(1):94-104. doi: 10.1038/onc.2015.65.

Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis.
Heinzle C, Gsur A, Hunjadi M, Erdem Z, Gauglhofer C, Stättner S, Karner J, Klimpfinger M, Wrba F, Reti A, Hegedus B, Baierl A, Grasl-Kraupp B, Holzmann K, Grusch M, Berger W, Marian B.;
Cancer Res. 2012 Nov 15;72(22):5767-77. doi: 10.1158/0008-5472.CAN-11-3654.

The combined use of known antiviral reverse transcriptase inhibitors AZT and DDI induce anticancer effects at low concentrations.
Aschacher T, Sampl S, Käser L, Bernhard D, Spittler A, Holzmann K, Bergmann M.;
Neoplasia. 2012 Jan;14(1):44-53.

Expression of telomeres in astrocytoma WHO grade 2 to 4: TERRA level correlates with telomere length, telomerase activity, and advanced clinical grade.
Sampl S, Pramhas S, Stern C, Preusser M, Marosi C, Holzmann K.;
Transl Oncol. 2012 Feb;5(1):56-65.

MNS16A tandem repeats minisatellite of human telomerase gene: a risk factor for colorectal cancer.
Hofer P, Baierl A, Feik E, Führlinger G, Leeb G, Mach K, Holzmann K, Micksche M, Gsur A.;
Carcinogenesis. 2011 Jun;32(6):866-71. doi: 10.1093/carcin/bgr053.

Telomere Transcripts Target Telomerase in Human Cancer Cells.
Kreilmeier T, Mejri D, Hauck M, Kleiter M, Holzmann K;
Genes (Basel). 2016 Aug 16;7(8). pii: E46. doi: 10.3390/genes7080046.

 

 

All Publications

PubmedDatabase

 
Drucken
 
 
© MedUni Wien | Impressum | Nutzungsbedingungen | Datenschutzerklärung | Barrierefreiheit | Kontakt